Inactive Instrument

PDL BioPharma, Inc.

Equities

PDLI

US69329Y1047

Biotechnology & Medical Research

Pdl Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020

May 07, 2020 at 10:05 pm

PDL BioPharma, Inc. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced total revenue was USD 5.995 million compared to USD 6.696 million a year ago. Net loss was USD 31.723 million compared to net income of USD 6.680 million a year ago. Basic loss per share was USD 0.26 compared to basic earnings per share of USD 0.05 a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.07 a year ago.

Latest news about PDL BioPharma, Inc.

PDL BioPharma, Inc.'s Equity Buyback announced on December 9, 2019 has expired with the repurchase of 15,532,000 shares, representing 12.91% for $50.39 million.	30/12/21	CI
Tranche Update on PDL BioPharma, Inc.'s Equity Buyback Plan announced on December 9, 2019.	29/03/21	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from S&P Global BMI Index	05/01/21	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from S&P TMI Index	05/01/21	CI
PDL BioPharma, Inc.(NasdaqGM:PDLI) dropped from NASDAQ Biotechnology Index	01/01/21	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2000 Dynamic Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2000 Value-Defensive Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2000 Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 3000 Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2500 Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2000 Value Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell Small Cap Completeness Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell Small Cap Comp Value Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2500 Value Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 3000 Value Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell Microcap Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 3000E Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 3000E Value Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell Microcap Value Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2000 Defensive Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2500 Defensive Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2500 Dynamic Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2000 Value-Dynamic Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2500 Value-Defensive Index	30/12/20	CI
PDL BioPharma, Inc.(NasdaqGS:PDLI) dropped from Russell 2500 Value-Dynamic Index	30/12/20	CI

Chart PDL BioPharma, Inc.

Duration

Period

More charts

Company Profile

PDL BioPharma, Inc. has a portfolio of income generating assets based on alternative financings. These alternative financings fall into one of three categories: royalty monetization, debt structures and hybrids of the two. The Company's investments are typically in assets with strong intellectual property protection and are commercial stage or soon-to-be approved. The counterparties in these transactions can be biotechs, pharmas, medtech companies, universities and inventors.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+50.63%	63.85B
IQVIA HOLDINGS INC.	-2.30%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+3.13%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.00%	12.11B
MEDPACE HOLDINGS, INC.	+27.97%	12.07B

Other Biotechnology & Medical Research